Capacitive-resistive Electric Transfer Therapy for Recovery From Running Fatigue (UPV/EHU)
Primary Purpose
Running, Fatigue
Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Capacitive-resistive electric transfer (Tecar) therapy
Sponsored by

About this trial
This is an interventional other trial for Running focused on measuring Capacitive-resistive electric transfer therapy, Radiofrequency therapy, Recovery intervention, Fatigue, Running
Eligibility Criteria
Inclusion Criteria:
- Recreationally active (current participation in races and a 10-km race time <34.5-min)
Exclusion Criteria:
- Suffered from any injury within the preceding 4 months.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
Tecar treatment group
Control group
Arm Description
The capacitive-resistive electric transfer (Tecar) therapy treatment group will receive 45 minutes of Tecar therapy treatment.
Participants will test passively in a sitting position for 30-min period
Outcomes
Primary Outcome Measures
CHANGE FROM BASELINE OXYGEN UPTAKE AT 48 HOURS AFTER THE TREATMENT.
Oxygen uptake (mL kg-1 min-1) will be assessed in an incremental running test on a treadmill (HP Cosmos pulsar, Nussdorf-Traunstein, Germany). Oxygen uptake will be recorded using a gas analyzer system (Esgostik Geratherm, Geschwenda, Germany).
CHANGE FROM BASELINE RESPIRATORY EXCHANGE RATIO AT 48 HOURS AFTER THE TREATMENT.
Respiratory exchange ratio (ratio between the amount of carbon dioxide (CO2) produced in metabolism and oxygen (O2)) will be assessed in an incremental running test on a treadmill (HP Cosmos pulsar, Nussdorf-Traunstein, Germany). Respiratory exchange ratio will be recorded using a gas analyzer system (Esgostik Geratherm, Geschwenda, Germany).
CHANGE FROM BASELINE VENTILATION AT 48 HOURS AFTER THE TREATMENT.
Ventilation (L• min-1) will be assessed in an incremental running test on a treadmill (HP Cosmos pulsar, Nussdorf-Traunstein, Germany). Ventilatory output will be recorded using a gas analyzer system (Esgostik Geratherm, Geschwenda, Germany).
CHANGE FROM BASELINE HEART RATE AT 48 HOURS AFTER THE TREATMENT.
Heart rate (beat • min-1) will be assessed in an incremental running test on a treadmill (HP Cosmos pulsar, Nussdorf-Traunstein, Germany). Heart rate will be recorded by a heart monitor (Polar RS800, Kempele, Finland).
CHANGE FROM BASELINE BLOOD LACTATE CONCENTRATION AT 48 HOURS AFTER THE TREATMENT.
- Blood lactate concentration (mmol •L-1) will be assessed in an incremental running test on a treadmill (HP Cosmos pulsar, Nussdorf-Traunstein, Germany). Capillary blood samples will be obtained in each test from the earlobe for the determination of blood lactate concentration by a portable lactate analyzer (Lactate, Arkray, KDK Corporation, Kyoto, Japan).
CHANGE FROM BASELINE STRIDE LENGTH AT 48 HOURS AFTER THE TREATMENT.
Stride length (cm), defined as the length the treadmill belt moves from toe-off to initial ground contact in successive steps, will be measured using an optical measurement system (Optojump-next, Microgate, Bolzano, Italy) placed at the treadmill belt level.
CHANGE FROM BASELINE STRIDE FREQUENCY AT 48 HOURS AFTER THE TREATMENT.
Stride frequency, defined as the number of ground contact events per minute, will be measured using an optical measurement system (Optojump-next, Microgate, Bolzano, Italy) placed at the treadmill belt level.
CHANGE FROM BASELINE STRIDE ANGLE AT 48 HOURS AFTER THE TREATMENT.
Stride angle (º), defined as the angle of the parable tangent derived from the theoretical arc traced by a foot during a stride and the ground, will be measured using an optical measurement system (Optojump-next, Microgate, Bolzano, Italy) placed at the treadmill belt level.
CHANGE FROM BASELINE GROUND CONTACT TIME AT 48 HOURS AFTER THE TREATMENT.
Ground contact time (s), defined as the time from when the foot contacts the ground to when the toes left the ground and was determined by the disruption of the infrared gates, will be measured using an optical measurement system (Optojump-next, Microgate, Bolzano, Italy) placed at the treadmill belt level.
CHANGE FROM BASELINE SWING TIME AT 48 HOURS AFTER THE TREATMENT.
The swing time (s) corresponds to the time from foot flat to initial take-off. Swing time will be measured using an optical measurement system (Optojump-next, Microgate, Bolzano, Italy) placed at the treadmill belt level.
CHANGE FROM BASELINE CONTACT PHASE AT 48 HOURS AFTER THE TREATMENT.
Contact phase (%), defined as the percentage of the ground contact time at which the different sub-phases of stance phase occur, will be measured using an optical measurement system (Optojump-next, Microgate, Bolzano, Italy) placed at the treadmill belt level.
CHANGE FROM BASELINE SUPPORT PHASE AT 48 HOURS AFTER THE TREATMENT.
The support sub-phase (%) corresponds to the time from initial ground contact to foot flat.
Support phase will be measured using an optical measurement system (Optojump-next, Microgate, Bolzano, Italy) placed at the treadmill belt level.
CHANGE FROM BASELINE PUSH-OFF PHASE AT 48 HOURS AFTER THE TREATMENT.
The push-off phase (%) corresponds to the time from initial take-off to toe-off.
Push-off phase will be measured using an optical measurement system (Optojump-next, Microgate, Bolzano, Italy) placed at the treadmill belt level.
Secondary Outcome Measures
Body height (cm)
Body height will be measured using a stadiometer (Año Sayol, Barcelona, Spain) following the guidelines outlined by the International Society for the Advancement of Kinanthropometry.
Body weight (kg)
Body weight will be measured using a balance (Año Sayol, Barcelona, Spain) following the guidelines outlined by the International Society for the Advancement of Kinanthropometry.
Full Information
NCT ID
NCT03317041
First Posted
October 10, 2017
Last Updated
October 17, 2017
Sponsor
University of the Basque Country (UPV/EHU)
1. Study Identification
Unique Protocol Identification Number
NCT03317041
Brief Title
Capacitive-resistive Electric Transfer Therapy for Recovery From Running Fatigue
Acronym
UPV/EHU
Official Title
Effects of a Capacitive-resistive Electric Transfer Therapy Exposure on Physiological and Biomechanical Parameters in Recreational Runners: a Randomized Controlled Crossover Trial
Study Type
Interventional
2. Study Status
Record Verification Date
October 2017
Overall Recruitment Status
Completed
Study Start Date
March 1, 2016 (Actual)
Primary Completion Date
July 31, 2016 (Actual)
Study Completion Date
September 28, 2016 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of the Basque Country (UPV/EHU)
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Reducing fatigue and improving the recovery capabilities of runners has gained more interest over the last years. Recently, capacitive-resistive electric transfer (Tecar) therapy is commonly used by physical therapists to help athletes recover from muscle fatigue. However, empiric evidence supporting the benefits of Tecar to recovery is lacking. This study investigated the effects of a Tecar treatment performed shortly after an exhausting training session on both physiological and biomechanical parameters of running.
Detailed Description
In this randomized controlled crossover trial all subjects will perform two test protocols separated by 2 weeks. Each protocol will comprise one exhausting training session (20-min warm-up consisted of 15-min of continuous self-paced running followed by 5-min of fast-finish progression runs increasing speeds (from approximately 60% to 80% of maximal heart rate, participant controlled), 10 x 500 m sprints at 90% of maximal heart rate with a 2-min rest period between bouts and a recovery phase consisting of 10-min of slow jogging). Twenty-four hours after this exhausting training, subjects will perform an incremental running test on a treadmill (Pre-intervention test) where subjects will start at 10 km/h for 6 min after which speed will be increased by 2 km/h every 6 min until a 16 km/h trial is completed. One hour after this test, in one protocol subjects will receive Tecar therapy (Tecar treatment group); in the other group (Control group) participants will rest passively in a sitting position for 30-min period. To evaluate the relevance of the changes induced by Tecar therapy/passive recovery, subjects will repeat the treadmill test 48 hours after the first test in both groups (72 hours after the exhaustive training).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Running, Fatigue
Keywords
Capacitive-resistive electric transfer therapy, Radiofrequency therapy, Recovery intervention, Fatigue, Running
7. Study Design
Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
14 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Tecar treatment group
Arm Type
Experimental
Arm Description
The capacitive-resistive electric transfer (Tecar) therapy treatment group will receive 45 minutes of Tecar therapy treatment.
Arm Title
Control group
Arm Type
No Intervention
Arm Description
Participants will test passively in a sitting position for 30-min period
Intervention Type
Other
Intervention Name(s)
Capacitive-resistive electric transfer (Tecar) therapy
Intervention Description
The Tecar treatment group will receive 45 minutes of Tecar therapy treatment. Subjects will lay down with the face down and two metallic plaques situated under each quadriceps muscle all over all the treatment. The treatment will start with the automatic capacitive energy transfer for 10-min where the capacitive plaque is situated on the sole of each foot with an elastic band. After that, the capacitive plaque will be pulled out. Then, the resistive electrode will be moved longitudinally through different muscles with massage lotion during 15-min per each lower extremity. The treatment will conclude with the automatic capacitive energy transfer for 10-min and the capacitive plaque situated on the sole of each foot with an elastic band.
Primary Outcome Measure Information:
Title
CHANGE FROM BASELINE OXYGEN UPTAKE AT 48 HOURS AFTER THE TREATMENT.
Description
Oxygen uptake (mL kg-1 min-1) will be assessed in an incremental running test on a treadmill (HP Cosmos pulsar, Nussdorf-Traunstein, Germany). Oxygen uptake will be recorded using a gas analyzer system (Esgostik Geratherm, Geschwenda, Germany).
Time Frame
Participants will be assessed at baseline (24 hours after an exhaustive training session) and at 48 hours after the treatment.
Title
CHANGE FROM BASELINE RESPIRATORY EXCHANGE RATIO AT 48 HOURS AFTER THE TREATMENT.
Description
Respiratory exchange ratio (ratio between the amount of carbon dioxide (CO2) produced in metabolism and oxygen (O2)) will be assessed in an incremental running test on a treadmill (HP Cosmos pulsar, Nussdorf-Traunstein, Germany). Respiratory exchange ratio will be recorded using a gas analyzer system (Esgostik Geratherm, Geschwenda, Germany).
Time Frame
Participants will be assessed at baseline (24 hours after an exhaustive training session) and at 48 hours after the treatment.
Title
CHANGE FROM BASELINE VENTILATION AT 48 HOURS AFTER THE TREATMENT.
Description
Ventilation (L• min-1) will be assessed in an incremental running test on a treadmill (HP Cosmos pulsar, Nussdorf-Traunstein, Germany). Ventilatory output will be recorded using a gas analyzer system (Esgostik Geratherm, Geschwenda, Germany).
Time Frame
Participants will be assessed at baseline (24 hours after an exhaustive training session) and at 48 hours after the treatment.
Title
CHANGE FROM BASELINE HEART RATE AT 48 HOURS AFTER THE TREATMENT.
Description
Heart rate (beat • min-1) will be assessed in an incremental running test on a treadmill (HP Cosmos pulsar, Nussdorf-Traunstein, Germany). Heart rate will be recorded by a heart monitor (Polar RS800, Kempele, Finland).
Time Frame
Participants will be assessed at baseline (24 hours after an exhaustive training session) and at 48 hours after the treatment.
Title
CHANGE FROM BASELINE BLOOD LACTATE CONCENTRATION AT 48 HOURS AFTER THE TREATMENT.
Description
- Blood lactate concentration (mmol •L-1) will be assessed in an incremental running test on a treadmill (HP Cosmos pulsar, Nussdorf-Traunstein, Germany). Capillary blood samples will be obtained in each test from the earlobe for the determination of blood lactate concentration by a portable lactate analyzer (Lactate, Arkray, KDK Corporation, Kyoto, Japan).
Time Frame
Participants will be assessed at baseline (24 hours after an exhaustive training session) and at 48 hours after the treatment.
Title
CHANGE FROM BASELINE STRIDE LENGTH AT 48 HOURS AFTER THE TREATMENT.
Description
Stride length (cm), defined as the length the treadmill belt moves from toe-off to initial ground contact in successive steps, will be measured using an optical measurement system (Optojump-next, Microgate, Bolzano, Italy) placed at the treadmill belt level.
Time Frame
Participants will be assessed at baseline (24 hours after an exhaustive training session) and at 48 hours after the treatment.
Title
CHANGE FROM BASELINE STRIDE FREQUENCY AT 48 HOURS AFTER THE TREATMENT.
Description
Stride frequency, defined as the number of ground contact events per minute, will be measured using an optical measurement system (Optojump-next, Microgate, Bolzano, Italy) placed at the treadmill belt level.
Time Frame
Participants will be assessed at baseline (24 hours after an exhaustive training session) and at 48 hours after the treatment.
Title
CHANGE FROM BASELINE STRIDE ANGLE AT 48 HOURS AFTER THE TREATMENT.
Description
Stride angle (º), defined as the angle of the parable tangent derived from the theoretical arc traced by a foot during a stride and the ground, will be measured using an optical measurement system (Optojump-next, Microgate, Bolzano, Italy) placed at the treadmill belt level.
Time Frame
Participants will be assessed at baseline (24 hours after an exhaustive training session) and at 48 hours after the treatment.
Title
CHANGE FROM BASELINE GROUND CONTACT TIME AT 48 HOURS AFTER THE TREATMENT.
Description
Ground contact time (s), defined as the time from when the foot contacts the ground to when the toes left the ground and was determined by the disruption of the infrared gates, will be measured using an optical measurement system (Optojump-next, Microgate, Bolzano, Italy) placed at the treadmill belt level.
Time Frame
Participants will be assessed at baseline (24 hours after an exhaustive training session) and at 48 hours after the treatment.
Title
CHANGE FROM BASELINE SWING TIME AT 48 HOURS AFTER THE TREATMENT.
Description
The swing time (s) corresponds to the time from foot flat to initial take-off. Swing time will be measured using an optical measurement system (Optojump-next, Microgate, Bolzano, Italy) placed at the treadmill belt level.
Time Frame
Participants will be assessed at baseline (24 hours after an exhaustive training session) and at 48 hours after the treatment.
Title
CHANGE FROM BASELINE CONTACT PHASE AT 48 HOURS AFTER THE TREATMENT.
Description
Contact phase (%), defined as the percentage of the ground contact time at which the different sub-phases of stance phase occur, will be measured using an optical measurement system (Optojump-next, Microgate, Bolzano, Italy) placed at the treadmill belt level.
Time Frame
Participants will be assessed at baseline (24 hours after an exhaustive training session) and at 48 hours after the treatment.
Title
CHANGE FROM BASELINE SUPPORT PHASE AT 48 HOURS AFTER THE TREATMENT.
Description
The support sub-phase (%) corresponds to the time from initial ground contact to foot flat.
Support phase will be measured using an optical measurement system (Optojump-next, Microgate, Bolzano, Italy) placed at the treadmill belt level.
Time Frame
Participants will be assessed at baseline (24 hours after an exhaustive training session) and at 48 hours after the treatment.
Title
CHANGE FROM BASELINE PUSH-OFF PHASE AT 48 HOURS AFTER THE TREATMENT.
Description
The push-off phase (%) corresponds to the time from initial take-off to toe-off.
Push-off phase will be measured using an optical measurement system (Optojump-next, Microgate, Bolzano, Italy) placed at the treadmill belt level.
Time Frame
Participants will be assessed at baseline (24 hours after an exhaustive training session) and at 48 hours after the treatment.
Secondary Outcome Measure Information:
Title
Body height (cm)
Description
Body height will be measured using a stadiometer (Año Sayol, Barcelona, Spain) following the guidelines outlined by the International Society for the Advancement of Kinanthropometry.
Time Frame
Participants will be assessed at baseline (24 hours after an exhaustive training session).
Title
Body weight (kg)
Description
Body weight will be measured using a balance (Año Sayol, Barcelona, Spain) following the guidelines outlined by the International Society for the Advancement of Kinanthropometry.
Time Frame
Participants will be assessed at baseline (24 hours after an exhaustive training session).
10. Eligibility
Sex
Male
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Recreationally active (current participation in races and a 10-km race time <34.5-min)
Exclusion Criteria:
Suffered from any injury within the preceding 4 months.
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Capacitive-resistive Electric Transfer Therapy for Recovery From Running Fatigue
We'll reach out to this number within 24 hrs